

EMERGING INVESTMENT LANDSCAPE IN HEALTH: WHAT REALLY MATTERS?

June 13, 2019

UCSF Mission Bay Campus Mission Hall 1401-2

[Click to Register](#)

Registration	3:30 - 4:00	All Attendees
Opening Keynote	4:00 - 5:00	Camille Samuels, Partner, Venrock Ventures
Panel Discussion	5:00 - 6:00	Tom Rodgers, SVP and Managing Director, McKesson Ventures Rebecca Lynn, Partner, Canvas Ventures Maria Sainz, President & CEO, Aegea Medical Anjali Joshi Consultant, Board Member, Advisor Ravi Srinivasan, Moderator Founder President and CEO, OncoNano Medicine
Speed Pitch Event	6:00 - 7:00	Six Company Pitches Ted Driscoll, Managing Director, DigitalDx Ventures Rajen Dalal, Soleno Therapeutics Stephanie Marrus, Director, Entrepreneurship Center at UCSF
Networking Reception	7:00 - 7:30	All Attendees

Keynote

Camille Samuels
Partner, Venrock



Camille Samuels is a Partner at Venrock, a venture capital firm originally established in the late 1960s as the venture arm of the Rockefeller family. Her investment interests span early-stage biotech to medical devices to consumer health. For instance, she serves on the board of directors of Unity biotech (UBX), a public longevity company — and is an observer on the board at Corvidia, a private cardiorenal company. She stepped off the board of RegenXBIO (RGNX) a year after it went public — and from Spirox after its acquisition by Entellus (and Stryker).

Prior to Venrock, Cami spent over a decade as a Managing Director at Versant Ventures, a leading life sciences venture capital firm. While at Versant, Cami seeded Kythera (makers of Kybella) and served on the company's board through its IPO and eventual sale to Allergan for \$2.1 B. In addition, she served as a board member or a board observer on many other innovative healthcare companies including Achaogen (AKAO), Carmenta (acq. by Progenity), Fluidigm (FLDM), Genomic Health (GHDX), Novacardia (acquired by Merck), ParAllele (acq. by Affymetrix), and Syrrx (acq. by Takeda).

Tom Rodgers leads the Venture efforts for McKesson (Fortune #6), which target and help scale emerging companies that are driving towards a stronger, more sustainable future for our health care industry. Specific focus for the fund is on technology-enabled services addressing the needs of pharma, pharmacy, providers and patients. Prior to rejoining McKesson, he spent more than a decade in health care venture capital, most recently leading strategic investing effort for Echo Health and before that with Advanced Technology Ventures. Before his venture career Tom had significant operating experience in the health care industry including various strategy and commercial roles at McKesson, Genentech, FitLinxx, and The Wilkerson Group. His investments include Hims, Accolade, Grail, AmericanWell, Evariant, Kyruus, Augmedix, Zeltiq (ZLTQ), Helixis (acquired by Illumina), and Aperiio (Acquired by Danaher). Tom holds an M.B.A. from the Wharton School, and a B.A. from the University of Pennsylvania. He was also an All-American Rugby player.



Panelist
Tom Rodgers
SVP and
Managing Director,
McKesson Ventures
Fortune #6

Panelist

Rebecca Lynn
Partner and Co-Founder,
Canvas Ventures



Rebecca Lynn is a general partner and co-founder of Canvas Ventures, where she focuses on early-stage venture investments in fintech, digital health and artificial intelligence. She was named a Top-20 VC by the New York Times in 2016 and a Top-100 VC in the annual "Midas List" by Forbes in 2018, 2017, 2016 and 2015.

Prior to co-founding Canvas, Rebecca led investments in Lending Club (NYSE: LC); Check (acquired by Intuit), and Doximity. While at Canvas, Rebecca led investments in FutureAdvisor (acquired by BlackRock), Casetext, Eden, Figure Eight, Gabi, HealthLoop, Luminar, Owl Camera, Roofstock, Vida Health, Viewics and 11 Honore. She began her career at Procter & Gamble's Cincinnati headquarters and later worked in Mexico where she launched products locally. She then joined NextCard, the world's first issuer of online credit cards, and became VP of Marketing and head of customer acquisition. Rebecca has a degree in chemical engineering from University of Missouri and a JD/MBA from University of California at Berkeley.

Maria Sainz was appointed President & CEO of AEGEA Medical in May 2018. She has over 25 years experience in commercial and leadership positions in the medtech industry. Maria has served as the President & CEO of Cardiokinetix, a medical device company pioneering a catheter-based treatment for heart failure. Prior to that, Maria was the President & CEO of Concentric Medical, Inc., a developer of minimally invasive products for the treatment of acute ischemic stroke which was acquired in 2011 by Stryker Corporation. Maria began her medtech career at Guidant Corporation where she held positions of increasing responsibility in Europe and the US. At the time of the acquisition of Guidant by Boston Scientific, Maria served as President of the Cardiac Surgery division of Guidant Corporation. Maria also serves as a Director of several public and private medical company boards. She received a M.A in Languages from the University Complutense in Madrid, Spain and a Masters in International Management from the American Graduate School of International Management.



Panelist
Maria Sainz
President & CEO,
AEGEA Medical

Panelist

Anjali Joshi
Consultant,
Board Member,
Advisor



Anjali Joshi was Vice President of Product Management at Google until March of 2019, where most recently she worked on Google's product efforts focused on emerging markets. Earlier she led the product development team for search and image search products. With the growth in the number of smartphones users, her focus was to build new search experiences optimized for mobile devices across all geographies and languages. Her team defined and launched products for search queries for news and health, built interactive experiences for TV shows, redefined image search, and launched photos search. Anjali has also led product management teams for Maps, Translate, News, Finance, and Global Infrastructure at Google. She also led the early Google efforts for Cloud services and Fiber networks.

She received her Master's degree in Management Science and Engineering from Stanford University, a Master's degree in Computer Engineering from the State University of New York, and a Bachelor's degree in Electrical Engineering from IIT, Kanpur. She was selected as one of the top 50 alumni who have graduated from the Indian Institute of Technology, Kanpur in the last 50 years and was given the Distinguished Alumni Award in 2017. She has served in advisory roles to start-ups and on the board of TIE, Silicon Valley. She currently serves on the board of the McClatchy Company and is an advisor to Clinikk Healthcare in India.

Dr. Ravi Srinivasan is a seasoned healthcare executive, serial entrepreneur and scientist. He is the Cofounder and CEO of OncoNano Medicine, a clinical stage company developing therapeutic and imaging products targeting pH disorders in diseases such as cancer. He has previously founded StemPar Sciences, an oncology company, and StrataGent Life Sciences, a dermatology company. Ravi is an inventor in over 50 patents and has developed award winning products such as the Microjet "patch-pump" for delivering injectables like insulin painlessly through the skin (Edison award 2010). He has also served in senior executive, product development and manufacturing roles in silicon valley healthcare companies including SEA Medical, Corium, and ForSight V5. Dr. Srinivasan received his Ph.D. in Chemical Engineering from the Massachusetts Institute of Technology and a B.Tech. from IIT Mumbai.



Moderator
Ravi Srinivasan, Ph.D
VP Strategy, EPPIC Global
Founder, President
and CEO of
OncoNano Medicine

